Skip to main content

Table 1 Baseline characteristics of the patients with mono-CA-BSI or mixed-CA/B-BSIs

From: Clinical characteristics, risk factors and outcomes of mixed Candida albicans/bacterial bloodstream infections

Characteristics

Total(n = 117)

Mono-CA-BSI(n = 93)

Mixed-CA/B-BSIs(n = 24)

Pvalue

Age, median years (IQR)

68 (59,75)

69 (59,76)

64 (47,74)

0.399

Male sex [n (%)]

68 (58.1%)

53 (56.9%)

15 (62.5%)

0.626

APACHE II score at the onset of candidemia (IQR)

17.0 (11.5,24.5)

17.0 (12.0,24.0)

17.5 (10.0,26.5)

0.863

SOFA score at the onset of candidemia (IQR)

6.0 (2.0,9.0)

5.0 (2.0,9.0)

6.5 (2.0,9.8)

0.494

Prior ICU stay (days) (IQR)

3.0 (0.0,14.0)

1.0 (0.0,11.0)

12.0 (8.0,17.8)

0.001

Prior hospital stay (days) (IQR)

14.0 (4.5,27.5)

12.0 (2.0,26.5)

19.0 (12.0,30.8)

0.031

Prior ventilation mechanical ventilation (days) (IQR)

1.0 (0.0,13.0)

1.0 (0.0,10.0)

11.0 (0.3,24.5)

0.013

Underlying disease [n (%)]

 Diabetes mellitus

28 (23.9%)

23 (24.7%)

5 (20.8%)

0.690

 Chronic cardiac dysfunction

24 (20.5%)

16 (17.2%)

8 (33.3%)

0.144

 Chronic obstructive pulmonary disease

5 (4.3%)

5 (5.4%)

0 (0%)

0.552

 Chronic renal insufficiency

9 (7.7%)

8 (8.6%)

1 (4.2%)

0.766

 Chronic hepatic insufficiency

14 (12.0%)

13 (14.0%)

1 (4.2%)

0.333

 Solid tumour

33 (28.2%)

28 (30.1%)

5 (20.8%)

0.368

 Haematological malignancy

1 (0.9%)

1 (1.1%)

0 (0%)

> 0.999

 Trauma

19 (16.2%)

14 (15.1%)

5 (20.8%)

0.708

 Burn injury

4 (3.4%)

2 (2.2%)

2 (8.3%)

0.186

 Transplant

14 (12.0%)

11 (11.8%)

3 (12.5%)

> 0.999

Immunocompromised [n (%)]

 Immunosuppressant therapy

6 (5.1%)

6 (6.5%)

0 (0.0%)

0.448

 Steroid therapy

6 (5.1%)

6 (6.5%)

0 (0.0%)

0.448

 Chemotherapy/radiation

7 (6.0%)

7 (7.5%)

0 (0.0%)

0.366

 Neutropenia

4 (3.4%)

3 (3.2%)

1 (4.2%)

> 0.999

Blood transfusion [n (%)]

40 (34.2%)

30 (32.2%)

10 (41.7%)

0.386

Hospitalization ward [n (%)]

 Medical

11 (9.4%)

11 (11.8%)

0 (0.0%)

0.168

 Surgical

28 (23.9%)

24 (25.8%)

4 (16.7%)

0.349

 ICU

78 (66.7%)

58 (62.4%)

20 (83.3%)

0.052

Nosocomial infection [n (%)]

112 (95.7%)

88 (94.6%)

24 (100%)

0.552

Life-sustaining treatments ≥24 h [n (%)]

 Invasive mechanical ventilation

65 (60.2%)

47 (54.7%)

18 (81.8%)

0.020

 Vasopressor

45 (38.5%)

34 (36.6%)

11 (45.8%)

0.405

 CRRT

30 (25.6%)

20 (21.5%)

10 (41.7%)

0.044

Catheterisation a [n (%)]

 Central venous catheterb

106 (90.6%)

83 (89.2%)

23 (95.8%)

0.553

  Hemodialysis catheterc

27 (23.1%)

17 (18.3%)

10 (41.7%)

0.015

  PICC

13 (11.1%)

10 (10.8%)

3 (12.5%)

> 0.999

  Peripheral arterial catheters

37 (31.6%)

29 (31.2%)

8 (33.3%)

0.840

 Drainage tube

77 (65.8%)

59 (63.4%)

18 (75.0%)

0.287

 Urethral catheter

106 (90.6%)

85 (91.4%)

21 (87.5%)

0.848

Presence of two or more central venous catheters

36 (30.8%)

24 (25.8%)

12 (50.0%)

0.022

Total parenteral nutrition [n (%)]

85 (72.6%)

65 (69.9%)

20 (83.3%)

0.188

Hypoproteinemia [n (%)]

49 (41.9%)

37 (39.8%)

12 (50.0%)

0.366

Surgery [n (%)]

77 (65.8%)

59 (63.4%)

18 (75.0%)

0.287

Abdominal

39 (33.3%)

32 (34.4%)

7 (29.2%)

0.627

  1. Notes: Bold, indicates P < 0.05
  2. Abbreviations: IQR interquartile range, COPD chronic obstructive pulmonary disorder, SOFA sequential organ failure assessment, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, CRRT continuous renal replacement therapy, PICC Peripherally inserted central catheters
  3. aIncluded patients who were required to be catheterised within 2 weeks of the first positive sample, regardless of whether or not the catheter was removed before diagnosis
  4. bNon-tunneled central venous catheters such as subclavian, internal jugular and femoral venous catheters excluding hemodialysis catheter and PICC
  5. cNon-tunneled temporary dialysis catheter